NASDAQ$EPIX
Essa Pharma Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
ESSA Pharma reported financial results for the fourth quarter and fiscal year ended September 30, 2023.
ESSA Pharma reported on the progress of masofaniten (EPI-7386), its novel N-terminal domain androgen receptor inhibitor, including Phase 1 dose escalation data showing tolerability and PSA reductions when combined with enzalutamide in mCRPC patients. The company is focused on executing the Phase 2 combination study of masofaniten and enzalutamide in mCRPC patients and investigating masofaniten in combination with other standard of care antiandrogens. They anticipate their cash runway will fund planned operations through 2025.
- Phase 1 dose escalation is complete for masofaniten/enzalutamide combination study in mCRPC patients.
- Compelling safety and efficacy data were reported at Prostate Cancer Foundation 2023 Scientific Retreat and ESMO 2023.
- A head-to-head Phase 2 dose expansion is underway evaluating masofaniten/enzalutamide combination versus enzalutamide monotherapy in mCRPC patients.
- The company expects its cash runway to fund planned operations through 2025.
Headline financials
Revenue & EPS history
Essa Pharma · Revenue · Quarterly
$0
Forward guidance
ESSA Pharma is focused on the Phase 2 combination study of masofaniten and enzalutamide in mCRPC patients and investigating masofaniten in combination with other standard of care antiandrogens. The company’s expected cash runway extends into 2025.
Tailwinds
- Accuracy of ESSA's financial projections
- Obtaining positive results of clinical trials
- Obtaining necessary regulatory approvals
- General business, market and economic conditions
- Favorable pharmaceutical properties of masofaniten
Headwinds
- Medical uncertainties
- Scientific uncertainties
- Business uncertainties
- Economic uncertainties
- Competitive uncertainties
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 10 quarterly earnings reports · overlaid with Q4 2023
-0.3%
Avg return
Earnings day
+1.1%
Avg return
5 days after
-3.2%
Avg return
30 days after
39%
13 / 33 earnings
Positive
+46.0%
Q1 2021
Best reaction
-34.9%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | +0.0% | +0.0% | -89.5% | |
| Q2 2025 | +1.2% | -1.8% | -1.2% | |
| Q1 2025 | -3.0% | +3.6% | -2.4% | |
| Q4 2024 | -1.2% | -1.8% | +7.4% | |
| Q3 2024 | -5.5% | -2.6% | +22.9% | |
| Q2 2024 | +4.6% | +4.9% | -21.3% | |
| Q1 2024 | +2.5% | -5.4% | -10.0% | |
| Q4 2023 | +3.2% | +16.4% | +58.7% | |
| Q3 2023 | -2.8% | -4.5% | -5.6% | |
| Q2 2023 | -4.1% | +2.7% | +8.6% | |
| Q1 2023 | +2.1% | +0.3% | -2.4% | |
| Q4 2022 | -6.9% | — | — | |
| Q3 2022 | +3.1% | — | — | |
| Q2 2022 | +5.4% | — | — | |
| Q1 2022 | +1.4% | — | — | |
| Q4 2021 | +0.6% | — | — | |
| Q3 2021 | -34.9% | — | — | |
| Q2 2021 | -1.8% | — | — | |
| Q1 2021 | +46.0% | — | — | |
| Q4 2020 | +8.6% | — | — | |
| Q1 2020 | +0.0% | — | — | |
| Q4 2019 | -0.2% | — | — | |
| Q1 2019 | +3.2% | — | — | |
| Q2 2019 | -8.7% | — | — | |
| Q4 2018 | -2.4% | — | — | |
| Q1 2018 | -8.1% | — | — | |
| Q4 2016 | +0.0% | — | — | |
| Q3 2016 | +0.0% | — | — | |
| Q2 2016 | -5.8% | — | — | |
| Q1 2016 | +2.2% | — | — | |
| Q4 2015 | -8.2% | — | — | |
| Q3 2015 | +0.0% | — | — | |
| Q2 2015 | +0.0% | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro